TY - JOUR
T1 - Activation of TGF-β signaling induces cell death via the unfolded protein response in Fuchs endothelial corneal dystrophy
AU - Okumura, Naoki
AU - Hashimoto, Keisuke
AU - Kitahara, Miu
AU - Okuda, Hirokazu
AU - Ueda, Emi
AU - Watanabe, Kyoko
AU - Nakahara, Makiko
AU - Sato, Takahiko
AU - Kinoshita, Shigeru
AU - Tourtas, Theofilos
AU - Schlötzer-Schrehardt, Ursula
AU - Kruse, Friedrich
AU - Koizumi, Noriko
N1 - Publisher Copyright:
© 2017 The Author(s).
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Fuchs endothelial corneal dystrophy (FECD) is a slowly progressive bilateral disease of corneal endothelium in which accumulation of extracellular matrix (ECM) and loss of corneal endothelial cells (CECs) are phenotypic features. The corneal endothelium maintains corneal transparency by regulating water hydration; consequently, corneal endothelial dysfunction causes serious vision loss. The only therapy for corneal haziness due to corneal endothelial diseases, including FECD, is corneal transplantation using donor corneas, and no pharmaceutical treatment is available. We provide evidence that the expression levels of transforming growth factor-β (TGF-β) isoforms and TGF-β receptors are high in the corneal endothelium of patients with FECD. A cell model based on patients with FECD shows that TGF-β signaling induced a chronic overload of ECM proteins to the endoplasmic reticulum (ER), thereby enhancing the formation of unfolded protein and triggering the intrinsic apoptotic pathway through the unfolded protein response (UPR). We propose that inhibition of TGF-β signaling may represent a novel therapeutic target that suppresses cell loss as well as the accumulation of ECM in FECD.
AB - Fuchs endothelial corneal dystrophy (FECD) is a slowly progressive bilateral disease of corneal endothelium in which accumulation of extracellular matrix (ECM) and loss of corneal endothelial cells (CECs) are phenotypic features. The corneal endothelium maintains corneal transparency by regulating water hydration; consequently, corneal endothelial dysfunction causes serious vision loss. The only therapy for corneal haziness due to corneal endothelial diseases, including FECD, is corneal transplantation using donor corneas, and no pharmaceutical treatment is available. We provide evidence that the expression levels of transforming growth factor-β (TGF-β) isoforms and TGF-β receptors are high in the corneal endothelium of patients with FECD. A cell model based on patients with FECD shows that TGF-β signaling induced a chronic overload of ECM proteins to the endoplasmic reticulum (ER), thereby enhancing the formation of unfolded protein and triggering the intrinsic apoptotic pathway through the unfolded protein response (UPR). We propose that inhibition of TGF-β signaling may represent a novel therapeutic target that suppresses cell loss as well as the accumulation of ECM in FECD.
UR - http://www.scopus.com/inward/record.url?scp=85026424642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026424642&partnerID=8YFLogxK
U2 - 10.1038/s41598-017-06924-3
DO - 10.1038/s41598-017-06924-3
M3 - Article
C2 - 28754918
AN - SCOPUS:85026424642
SN - 2045-2322
VL - 7
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 6801
ER -